October 22nd 2024
Under terms of the deal, Sanofi would sell a 50% controlling stake in Opella to CD&R, while remaining a significant shareholder.
Roche Ends Agreement With Repare Therapeutics to Develop ATR Inhibitor Camonsertib
February 13th 2024Roche halts agreement with Repare Therapeutics to develop and commercialize camonsertib just weeks after triggering a $40 million milestone payment when the first patient was dosed with the novel cancer drug.